Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients

Mehmet Artac,Levent Korkmaz,Hasan Senol Coskun,Faysal Dane,Bulent Karabulut,Mustafa Karaağaç,Devrim Cabuk,Senem Karabulut,Nuri Faruk Aykan,Hatice Doruk,Nilufer Avci,N. S. Turhal

Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients

2019

Mehmet Artac
Levent Korkmaz
Hasan Senol Coskun
Faysal Dane
Bulent Karabulut
Mustafa Karaağaç
Devrim Cabuk
Senem Karabulut
Nuri Faruk Aykan
Hatice Doruk
Nilufer Avci
N. S. Turhal

Purpose The purpose of this study was to investigate whether obesity affects survival in metastatic colorectal cancer (mCRC) patients treated with bevacizumab combined with chemotherapy.

Keywords:

Obesity
General surgery
Bevacizumab
Colorectal cancer
Body mass index
Medicine
Chemotherapy
KRAS
Primary tumor
Survival rate
Oncology
Internal medicine
Radiation therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations